Collectively, these results demonstrate that in this luminal-like BC, RL inhibition improves the anti-tumor response to anti-CTLA4 (in the early setting) and anti-PD-L1 (for established tumors) through inhibition of RANK signaling in the tumor cells. This evidence concerns the gene CD274 and neoplasm.